Impact of Immunotherapy on Real-World Survival Outcomes in Metastatic Renal Cell Carcinoma

ConclusionIn real-world patients with mRCC, immunotherapy is associated with significant survival benefit. The present retrospective analysis shows the real-world benefit of second-line immunotherapy in patients previously treated with tyrosine –kinase inhibitors.
Source: Targeted Oncology - Category: Cancer & Oncology Source Type: research